ATE368647T1 - Pharmazeutische zusammensetzung und ihre verwendung als inhibitoren von der dipeptidyl peptidase iv (dpp-iv) - Google Patents
Pharmazeutische zusammensetzung und ihre verwendung als inhibitoren von der dipeptidyl peptidase iv (dpp-iv)Info
- Publication number
- ATE368647T1 ATE368647T1 AT03774478T AT03774478T ATE368647T1 AT E368647 T1 ATE368647 T1 AT E368647T1 AT 03774478 T AT03774478 T AT 03774478T AT 03774478 T AT03774478 T AT 03774478T AT E368647 T1 ATE368647 T1 AT E368647T1
- Authority
- AT
- Austria
- Prior art keywords
- dpp
- dipeptidyl peptidase
- inhibitors
- pharmaceutical composition
- diabetes
- Prior art date
Links
- 102000016622 Dipeptidyl Peptidase 4 Human genes 0.000 title abstract 4
- 101000930822 Giardia intestinalis Dipeptidyl-peptidase 4 Proteins 0.000 title abstract 4
- 239000003112 inhibitor Substances 0.000 title 1
- 239000008194 pharmaceutical composition Substances 0.000 title 1
- 201000001320 Atherosclerosis Diseases 0.000 abstract 1
- 206010060378 Hyperinsulinaemia Diseases 0.000 abstract 1
- 208000008589 Obesity Diseases 0.000 abstract 1
- 150000001875 compounds Chemical class 0.000 abstract 1
- 206010012601 diabetes mellitus Diseases 0.000 abstract 1
- 201000010099 disease Diseases 0.000 abstract 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 1
- 201000001421 hyperglycemia Diseases 0.000 abstract 1
- 230000003451 hyperinsulinaemic effect Effects 0.000 abstract 1
- 201000008980 hyperinsulinism Diseases 0.000 abstract 1
- 230000002519 immonomodulatory effect Effects 0.000 abstract 1
- 235000020824 obesity Nutrition 0.000 abstract 1
- 230000002265 prevention Effects 0.000 abstract 1
- 229940002612 prodrug Drugs 0.000 abstract 1
- 239000000651 prodrug Substances 0.000 abstract 1
- 150000003839 salts Chemical class 0.000 abstract 1
- 208000011580 syndromic disease Diseases 0.000 abstract 1
- 208000001072 type 2 diabetes mellitus Diseases 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
- C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D207/18—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having one double bond between ring members or between a ring member and a non-ring member
- C07D207/22—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having one double bond between ring members or between a ring member and a non-ring member with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D207/24—Oxygen or sulfur atoms
- C07D207/26—2-Pyrrolidones
- C07D207/263—2-Pyrrolidones with only hydrogen atoms or radicals containing only hydrogen and carbon atoms directly attached to other ring carbon atoms
- C07D207/27—2-Pyrrolidones with only hydrogen atoms or radicals containing only hydrogen and carbon atoms directly attached to other ring carbon atoms with substituted hydrocarbon radicals directly attached to the ring nitrogen atom
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
- C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D207/04—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
- C07D207/10—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D207/16—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/48—Drugs for disorders of the endocrine system of the pancreatic hormones
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/48—Drugs for disorders of the endocrine system of the pancreatic hormones
- A61P5/50—Drugs for disorders of the endocrine system of the pancreatic hormones for increasing or potentiating the activity of insulin
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
- C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
- C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Diabetes (AREA)
- Public Health (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- General Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Endocrinology (AREA)
- Obesity (AREA)
- Hematology (AREA)
- Immunology (AREA)
- Emergency Medicine (AREA)
- Child & Adolescent Psychology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Pyrrole Compounds (AREA)
- Pyridine Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US24683102A | 2002-09-19 | 2002-09-19 | |
| US10/659,860 US20040121964A1 (en) | 2002-09-19 | 2003-09-11 | Pharmaceutical compositions as inhibitors of dipeptidyl peptidase-IV (DPP-IV) |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| ATE368647T1 true ATE368647T1 (de) | 2007-08-15 |
Family
ID=32033228
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| AT03774478T ATE368647T1 (de) | 2002-09-19 | 2003-09-15 | Pharmazeutische zusammensetzung und ihre verwendung als inhibitoren von der dipeptidyl peptidase iv (dpp-iv) |
Country Status (20)
| Country | Link |
|---|---|
| EP (1) | EP1560811B9 (de) |
| JP (1) | JP4712387B2 (de) |
| KR (1) | KR101072236B1 (de) |
| CN (1) | CN101676264A (de) |
| AT (1) | ATE368647T1 (de) |
| AU (1) | AU2003282800B2 (de) |
| BR (1) | BR0314582A (de) |
| CA (2) | CA2768674A1 (de) |
| CY (1) | CY1110361T1 (de) |
| DE (1) | DE60315336T2 (de) |
| DK (1) | DK1560811T3 (de) |
| ES (1) | ES2290511T3 (de) |
| IL (1) | IL167434A (de) |
| MX (1) | MXPA05003091A (de) |
| NZ (1) | NZ538567A (de) |
| PL (1) | PL374732A1 (de) |
| PT (1) | PT1560811E (de) |
| TW (1) | TWI320406B (de) |
| WO (1) | WO2004026822A2 (de) |
| ZA (1) | ZA200502218B (de) |
Families Citing this family (59)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20040242568A1 (en) | 2003-03-25 | 2004-12-02 | Syrrx, Inc. | Dipeptidyl peptidase inhibitors |
| EP1620091B1 (de) | 2003-05-05 | 2010-03-31 | Probiodrug AG | Glutaminylcyclase-hemmer |
| JP2007511467A (ja) | 2003-05-14 | 2007-05-10 | タケダ サン ディエゴ インコーポレイテッド | ジペプチジルペプチダーゼインヒビター |
| MXPA06001601A (es) | 2003-08-13 | 2006-08-25 | Takeda Pharmaceutical | Derivados de 4-pirimidona y su uso como inhibidores de dipeptidilpeptidasa. |
| WO2005023762A1 (en) * | 2003-09-04 | 2005-03-17 | Abbott Laboratories | Pyrrolidine-2-carbonitrile derivatives and their use as inhibitors of dipeptidyl peptidase-iv (dpp-iv) |
| US7205409B2 (en) | 2003-09-04 | 2007-04-17 | Abbott Laboratories | Pharmaceutical compositions as inhibitors of dipeptidyl peptidase-IV (DPP-IV) |
| WO2005073186A1 (ja) * | 2004-01-29 | 2005-08-11 | Ono Pharmaceutical Co., Ltd. | ピロリジン誘導体 |
| ATE537141T1 (de) | 2004-02-05 | 2011-12-15 | Kyorin Seiyaku Kk | Bicycloesterderivat |
| WO2005095339A1 (en) * | 2004-03-31 | 2005-10-13 | Pfizer Products Inc. | Dicyanopyrrolidines as dipeptidyl peptidase iv inhibitors |
| WO2005116029A1 (en) * | 2004-05-18 | 2005-12-08 | Merck & Co., Inc. | Cyclohexylalanine derivatives as dipeptidyl peptidase-iv inhibitors for the treatment or prevention of diabetes |
| MXPA06015169A (es) * | 2004-07-08 | 2007-08-21 | Warner Lambert Co | Moduladores de androgenos. |
| WO2006011035A1 (en) * | 2004-07-23 | 2006-02-02 | Glenmark Pharmaceuticals Ltd. | Novel dipeptidyl peptidase iv inhibitors; process for their preparation and compositions containing them |
| EP1794120B1 (de) * | 2004-07-23 | 2012-04-11 | Nuada, LLC | Peptidaseinhibitoren |
| AU2005293266B2 (en) | 2004-10-12 | 2011-09-29 | Glenmark Pharmaceuticals S.A. | Novel dipeptidyl peptidase IV inhibitors, pharmaceutical compositions containing them, and process for their preparation |
| JP2008019168A (ja) * | 2004-10-22 | 2008-01-31 | Astellas Pharma Inc | ２−シアノ−４−フルオロピロリジン誘導体の製造法 |
| JPWO2006118196A1 (ja) * | 2005-04-27 | 2008-12-18 | 味の素株式会社 | Ｄｐｐ４阻害剤及びその医薬用途 |
| EP1931633A2 (de) * | 2005-09-05 | 2008-06-18 | Ranbaxy Laboratories Limited | 3-azabicyclo[3.1.0]hexan-derivate als dipeptidylpeptidase-iv-hemmer |
| NZ566799A (en) | 2005-09-14 | 2011-04-29 | Takeda Pharmaceutical | Dipeptidyl peptidase inhibitors for treating diabetes |
| WO2007035629A2 (en) | 2005-09-16 | 2007-03-29 | Takeda Pharmaceutical Company Limited | Process for the preparation of pyrimidinedione derivatives |
| GB0526291D0 (en) | 2005-12-23 | 2006-02-01 | Prosidion Ltd | Therapeutic method |
| US7915427B2 (en) | 2006-03-08 | 2011-03-29 | Kyorin Pharmaceuticals Co., Ltd. | Process for producing aminoacetyl pyrrolidine carbonitrile derivative and intermediate for production thereof |
| WO2007112347A1 (en) | 2006-03-28 | 2007-10-04 | Takeda Pharmaceutical Company Limited | Dipeptidyl peptidase inhibitors |
| EP2004601B1 (de) * | 2006-04-03 | 2011-03-02 | Matrix Laboratories Limited | Neue dipeptidylpeptidase-iv-inhibitoren und verfahren zur ihrer herstellung und pharmazeutische zusammensetzung, die diese enthalten |
| AU2007235876A1 (en) | 2006-04-12 | 2007-10-18 | Probiodrug Ag | Enzyme inhibitors |
| CN101516872A (zh) * | 2006-07-20 | 2009-08-26 | 艾博特公司 | (2s,5r)-5-乙炔基-1-{n-(4-甲基-1-(4-羧基-吡啶-2-基)哌啶-4-基)甘氨酰}吡咯烷-2-甲腈的合成 |
| US8324383B2 (en) | 2006-09-13 | 2012-12-04 | Takeda Pharmaceutical Company Limited | Methods of making polymorphs of benzoate salt of 2-[[6-[(3R)-3-amino-1-piperidinyl]-3,4-dihydro-3-methyl-2,4-dioxo-1(2H)-pyrimidinyl]methyl]-benzonitrile |
| US8278345B2 (en) | 2006-11-09 | 2012-10-02 | Probiodrug Ag | Inhibitors of glutaminyl cyclase |
| TW200838536A (en) | 2006-11-29 | 2008-10-01 | Takeda Pharmaceutical | Polymorphs of succinate salt of 2-[6-(3-amino-piperidin-1-yl)-3-methyl-2,4-dioxo-3,4-dihydro-2H-pyrimidin-1-ylmethy]-4-fluor-benzonitrile and methods of use therefor |
| ATE554085T1 (de) | 2006-11-30 | 2012-05-15 | Probiodrug Ag | Neue inhibitoren von glutaminylcyclase |
| US8093236B2 (en) | 2007-03-13 | 2012-01-10 | Takeda Pharmaceuticals Company Limited | Weekly administration of dipeptidyl peptidase inhibitors |
| JPWO2008114857A1 (ja) | 2007-03-22 | 2010-07-08 | 杏林製薬株式会社 | アミノアセチルピロリジンカルボニトリル誘導体の製造方法 |
| WO2008128985A1 (en) | 2007-04-18 | 2008-10-30 | Probiodrug Ag | Thiourea derivatives as glutaminyl cyclase inhibitors |
| GB2465132B (en) | 2007-09-21 | 2012-06-06 | Lupin Ltd | Compounds as dipeptidyl peptidase IV (DPP IV) inhibitors |
| JP5476305B2 (ja) | 2008-08-07 | 2014-04-23 | 杏林製薬株式会社 | ビシクロ［２．２．２］オクチルアミン誘導体の製造方法 |
| GB2483614B (en) | 2009-06-18 | 2014-12-03 | Lupin Ltd | 2-Amino-2- [8-(dimethyl carbamoyl)- 8-aza- bicyclo [3.2.1] oct-3-yl]-exo- ethanoyl derivatives as potent dpp-iv inhibitors |
| AR077642A1 (es) | 2009-07-09 | 2011-09-14 | Arena Pharm Inc | Moduladores del metabolismo y el tratamiento de trastornos relacionados con el mismo |
| PL2475428T3 (pl) | 2009-09-11 | 2015-12-31 | Probiodrug Ag | Pochodne heterocykliczne jako inhibitory cyklazy glutaminowej |
| ES2586231T3 (es) | 2010-03-03 | 2016-10-13 | Probiodrug Ag | Inhibidores de glutaminil ciclasa |
| MX2012010470A (es) | 2010-03-10 | 2012-10-09 | Probiodrug Ag | Inhibidores heterociclicos d ciclasa de glutaminilo (qc, ec .3 2. 5). |
| EP2544684B1 (de) * | 2010-03-10 | 2014-12-24 | Janssen Pharmaceutica NV | 4,4-disubstituierte piperidinderivate als hemmer von dipeptidylpeptidase-1 (dpp-1) |
| JP2013523819A (ja) | 2010-04-06 | 2013-06-17 | アリーナ ファーマシューティカルズ， インコーポレイテッド | Ｇｐｒ１１９レセプターのモジュレーターおよびそれに関連する障害の処置 |
| US8541596B2 (en) | 2010-04-21 | 2013-09-24 | Probiodrug Ag | Inhibitors |
| TWI403716B (zh) * | 2010-08-13 | 2013-08-01 | Nat Univ Tsing Hua | 氫氣檢測器、系統及方法 |
| CN103221410B (zh) | 2010-09-22 | 2017-09-15 | 艾尼纳制药公司 | Gpr119受体调节剂和对与其相关的障碍的治疗 |
| EP2686313B1 (de) | 2011-03-16 | 2016-02-03 | Probiodrug AG | Benzimidazolderivate als glutaminylcyclase-hemmer |
| US20140018371A1 (en) | 2011-04-01 | 2014-01-16 | Arena Pharmaceuticals, Inc. | Modulators Of The GPR119 Receptor And The Treatment Of Disorders Related Thereto |
| WO2012145361A1 (en) | 2011-04-19 | 2012-10-26 | Arena Pharmaceuticals, Inc. | Modulators of the gpr119 receptor and the treatment of disorders related thereto |
| WO2012145604A1 (en) | 2011-04-22 | 2012-10-26 | Arena Pharmaceuticals, Inc. | Modulators of the gpr119 receptor and the treatment of disorders related thereto |
| WO2012145603A1 (en) | 2011-04-22 | 2012-10-26 | Arena Pharmaceuticals, Inc. | Modulators of the gpr119 receptor and the treatment of disorders related thereto |
| WO2012170702A1 (en) | 2011-06-08 | 2012-12-13 | Arena Pharmaceuticals, Inc. | Modulators of the gpr119 receptor and the treatment of disorders related thereto |
| WO2013055910A1 (en) | 2011-10-12 | 2013-04-18 | Arena Pharmaceuticals, Inc. | Modulators of the gpr119 receptor and the treatment of disorders related thereto |
| TWI500613B (zh) | 2012-10-17 | 2015-09-21 | Cadila Healthcare Ltd | 新穎之雜環化合物 |
| WO2014074668A1 (en) | 2012-11-08 | 2014-05-15 | Arena Pharmaceuticals, Inc. | Modulators of gpr119 and the treatment of disorders related thereto |
| CN105399700A (zh) * | 2013-01-06 | 2016-03-16 | 天津市汉康医药生物技术有限公司 | 噻唑烷衍生物、其制备方法和用途 |
| JP6590226B2 (ja) * | 2016-05-11 | 2019-10-16 | 株式会社シード探索研究所 | オキサアジリジン化合物およびその製造方法 |
| WO2018049027A1 (en) * | 2016-09-07 | 2018-03-15 | Trustees Of Tufts College | Combination therapies using immuno-dash inhibitors and pge2 antagonists |
| PL3461819T3 (pl) | 2017-09-29 | 2020-11-30 | Probiodrug Ag | Inhibitory cyklazy glutaminylowej |
| CN116283702B (zh) * | 2021-12-24 | 2025-06-03 | 西南医科大学 | 一类具有抗糖尿病活性的化合物及其制备方法和应用 |
| WO2025264645A1 (en) * | 2024-06-18 | 2025-12-26 | Latigo Biotherapeutics, Inc. | Sodium channel blocking compounds, derivatives thereof, and methods of their use |
Family Cites Families (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| FR2678938B1 (fr) * | 1991-07-10 | 1993-10-08 | Rhone Poulenc Rorer Sa | Derives de pyrrolidine, leur preparation et les medicaments les contenant. |
| US5691356A (en) * | 1994-03-21 | 1997-11-25 | Bristol-Myers Squibb Company | Disubstituted heterocyclic thrombin inhibitors |
| CO5150173A1 (es) * | 1998-12-10 | 2002-04-29 | Novartis Ag | Compuestos n-(glicilo sustituido)-2-cianopirrolidinas inhibidores de peptidasa de dipeptidilo-iv (dpp-iv) los cuales son efectivos en el tratamiento de condiciones mediadas por la inhibicion de dpp-iv |
| US6172081B1 (en) | 1999-06-24 | 2001-01-09 | Novartis Ag | Tetrahydroisoquinoline 3-carboxamide derivatives |
| TW583185B (en) * | 2000-06-13 | 2004-04-11 | Novartis Ag | N-(substituted glycyl)-2-cyanopyrrolidines and pharmaceutical composition for inhibiting dipeptidyl peptidase-IV (DPP-IV) or for the prevention or treatment of diseases or conditions associated with elevated levels of DPP-IV comprising the same |
-
2003
- 2003-09-15 DK DK03774478T patent/DK1560811T3/da active
- 2003-09-15 WO PCT/US2003/029018 patent/WO2004026822A2/en not_active Ceased
- 2003-09-15 KR KR1020057004773A patent/KR101072236B1/ko not_active Expired - Fee Related
- 2003-09-15 PT PT03774478T patent/PT1560811E/pt unknown
- 2003-09-15 NZ NZ538567A patent/NZ538567A/en not_active IP Right Cessation
- 2003-09-15 AU AU2003282800A patent/AU2003282800B2/en not_active Ceased
- 2003-09-15 ES ES03774478T patent/ES2290511T3/es not_active Expired - Lifetime
- 2003-09-15 JP JP2004537831A patent/JP4712387B2/ja not_active Expired - Fee Related
- 2003-09-15 BR BR0314582-4A patent/BR0314582A/pt not_active IP Right Cessation
- 2003-09-15 DE DE60315336T patent/DE60315336T2/de not_active Expired - Lifetime
- 2003-09-15 CA CA2768674A patent/CA2768674A1/en not_active Abandoned
- 2003-09-15 EP EP03774478A patent/EP1560811B9/de not_active Expired - Lifetime
- 2003-09-15 PL PL03374732A patent/PL374732A1/xx unknown
- 2003-09-15 MX MXPA05003091A patent/MXPA05003091A/es active IP Right Grant
- 2003-09-15 CN CN200910166852A patent/CN101676264A/zh active Pending
- 2003-09-15 CA CA2497725A patent/CA2497725C/en not_active Expired - Fee Related
- 2003-09-15 AT AT03774478T patent/ATE368647T1/de active
- 2003-09-19 TW TW092125921A patent/TWI320406B/zh not_active IP Right Cessation
-
2005
- 2005-02-16 ZA ZA2005/02218A patent/ZA200502218B/en unknown
- 2005-03-15 IL IL167434A patent/IL167434A/en not_active IP Right Cessation
-
2007
- 2007-10-23 CY CY20071101364T patent/CY1110361T1/el unknown
Also Published As
| Publication number | Publication date |
|---|---|
| WO2004026822A3 (en) | 2004-05-06 |
| WO2004026822A2 (en) | 2004-04-01 |
| DE60315336D1 (de) | 2007-09-13 |
| JP2006503057A (ja) | 2006-01-26 |
| KR20050043981A (ko) | 2005-05-11 |
| DK1560811T3 (da) | 2007-12-10 |
| CY1110361T1 (el) | 2015-04-29 |
| TW200417545A (en) | 2004-09-16 |
| PT1560811E (pt) | 2007-11-14 |
| CA2497725C (en) | 2012-04-10 |
| MXPA05003091A (es) | 2005-05-27 |
| EP1560811A2 (de) | 2005-08-10 |
| HK1082733A1 (en) | 2006-06-16 |
| CA2768674A1 (en) | 2004-04-01 |
| BR0314582A (pt) | 2005-08-09 |
| KR101072236B1 (ko) | 2011-10-12 |
| AU2003282800A1 (en) | 2004-04-08 |
| EP1560811B1 (de) | 2007-08-01 |
| CN101676264A (zh) | 2010-03-24 |
| ES2290511T3 (es) | 2008-02-16 |
| EP1560811B9 (de) | 2008-03-05 |
| TWI320406B (en) | 2010-02-11 |
| ZA200502218B (en) | 2005-11-30 |
| PL374732A1 (en) | 2005-10-31 |
| IL167434A (en) | 2010-12-30 |
| AU2003282800B2 (en) | 2009-10-29 |
| DE60315336T2 (de) | 2008-05-08 |
| JP4712387B2 (ja) | 2011-06-29 |
| CA2497725A1 (en) | 2004-04-01 |
| NZ538567A (en) | 2007-04-27 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| DE60315336D1 (de) | Pharmazeutische zusammensetzung und ihre verwendung als inhibitoren von der dipeptidyl peptidase iv (dpp-iv) | |
| BR0315796A (pt) | Composto, composição farmacêutica, e, métodos para tratar diabetes, para tratar hiperglicemia, e para tratar obesidade em um mamìfero | |
| EP1554280A4 (de) | Antidiabetische heterocyclische beta-aminoverbindungen als inhibitoren von dipeptidylpeptidase | |
| MXPA04003759A (es) | Derivados de pirrolidin n-substituido como inhibidores de dipeptidil peptidasa iv. | |
| ATE419848T1 (de) | Cycloalkyl-lactam-derivate als inhibitoren von 11-beta-hydroxysteroiddehydrogenase 1 | |
| CL2004000437A1 (es) | Compuestos heterociclicos del tipo [1,4]-diazepan-2-ona sustituidos, inhibidores de la enzima dipeptidilpeptidasa-iv (cdp-iv); composicion farmaceutica; y su uso para preparar un medicamento para tratar hiperglucemia, diabetes tipo 2, obesidad, trast | |
| ATE453393T1 (de) | Verwendung von pyridylamiden als angiogenesehemmer | |
| WO2004037181A3 (en) | Glycinenitrile-based inhibitors of dipeptidyl peptidase iv and methods | |
| HUP0303876A3 (en) | Preparation of pharmaceutical compositions for treatment of type 2 diabetes using piperidine or tiazolidine, inhibitors of dipeptidyl peptidase iv | |
| DE602004026440D1 (de) | Kondensierte indole als dipeptidyl-peptidase-hemmer zur behandlung oder prävention von diabetes | |
| WO2004050022A3 (en) | Phenylalanine derivatives as dipeptidyl peptidase inhibitors for the treatment or prevention of diabetes | |
| ATE318139T1 (de) | Dipeptidylpeptidase-hemmer zur behandlung von diabetes | |
| WO2006058064A3 (en) | Fused aminopiperidines as dipeptidyl peptidase-iv inhibitors for the treatment or prevention of diabetes | |
| TNSN08367A1 (en) | Aminotetrahydropyrans as dipeptidyl peptidase-iv inhibitors for the treatment or prevention of diabetes | |
| EA200501936A1 (ru) | Производные пиридо[2,1-a]изохинолина в качестве ингибиторов dpp-iv | |
| ATE396190T1 (de) | Substituierte heteroarylalkansäure und ihre verwendung als inhibitoren der aldose reductase | |
| PT1280797E (pt) | Inibidores da peptidase iv de dipeptidilo | |
| DE602004008959D1 (de) | Benzoäbüä1,4üdioxepinderivate | |
| SE0102300D0 (sv) | Compounds | |
| MXPA05001712A (es) | Bifenilcarboxamidas sustituidas con n-aril piperidina como inhibidores de la secrecion de apolipoproteina b. | |
| BR0212899A (pt) | Compostos orgânicos | |
| ATE548350T1 (de) | N-arylpiperidin-substituierte biphenylcarbonsäureamide als inhibitoren von apolipoprotein b | |
| SG141430A1 (en) | Substituted pyrrole derivatives and their use as hmg-co inhibitors | |
| TW200500338A (en) | Phenylalanine derivatives as dipeptidyl peptidase inhibitors for the treatment or prevention of diabetes |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| UEP | Publication of translation of european patent specification |
Ref document number: 1560811 Country of ref document: EP |